Leriglitazone halts progression of fatal neurodegenerative disorder
Drug Discovery World
JUNE 21, 2024
Leriglitazone has been shown to halt disease progression in adult patients with early cerebral adrenoleukodystrophy (cALD) in a compassionate-use study. cALD is a fatal neurodegenerative disorder that is characterised by growing, demyelinating brain lesions, with death occurring typically within three to four years of onset. The study was led by Fanny Mochel, Professor at the Hôspital Universitaire La Pitié-Salpêtrière (Paris, France), as part of an early-access programme through the French nati
Let's personalize your content